dna pk tor kinase inhibitor cc 115

Drug Overview

The medication known as CC-115 is a cutting-edge “Smart Drug” designed to treat several types of advanced cancers. It is a highly specialized medical tool that acts as a dual-action inhibitor. Instead of attacking all fast-growing cells like traditional chemotherapy, CC-115 targets specific survival engines inside cancer cells to stop them from growing and repairing themselves.

Here are the key details about this agent:

• Generic Name: CC-115.
• US Brand Names: None yet. It is currently an investigational drug used in clinical trials.
• Drug Class: Dual DNA-PK and mTOR Kinase Inhibitor / Targeted Therapy.
• Route of Administration: Oral (taken by mouth as a tablet).
• FDA Approval Status: Investigational. It is not yet FDA-approved for standard public use, but it has received “Orphan Drug” designation for specific conditions like glioblastoma and is being actively studied in advanced clinical trials.
  
  Discover the dna pk tor kinase inhibitor cc 115. Our specialized hospital provides expert oncology care, targeted therapies, and clinical trial options.

What Is It and How Does It Work? (Mechanism of Action)

To understand how CC-115 works, it helps to think of a cancer cell as a high-tech machine that has two main systems: a “Growth Engine” and a “Repair Crew.” CC-115 is designed to sabotage both at the same time.

The Growth Engine (mTOR Kinase)

Most cancer cells rely on a protein called mTOR (mammalian target of rapamycin). This protein acts like a master switch that tells the cell to eat, grow, and divide. In many cancers, this switch is stuck in the “ON” position. CC-115 binds to the mTOR kinase and flips the switch to “OFF,” effectively starving the cancer cell of the signals it needs to multiply.

The Repair Crew (DNA-PK)

Cancer cells often have damaged DNA, but they survive because they have a specialized “Repair Crew” protein called DNA-dependent protein kinase (DNA-PK). This protein identifies breaks in the cell’s genetic code and stitches them back together.

Molecular Double-Blockade

When CC-115 enters the body, it performs a unique double-action:

1. Blocking mTOR: It stops the cell from growing and prevents it from becoming resistant to other treatments.
2. Blocking DNA-PK: It prevents the cell from fixing its own DNA. When the DNA damage becomes too great and the growth signals are gone, the cancer cell undergoes Apoptosis (programmed cell death).

By targeting both pathways, CC-115 makes it much harder for cancer cells to adapt or survive, especially in aggressive tumors like brain cancer or chronic leukemias.

FDA-Approved Clinical Indications

Because CC-115 is an investigational agent, it does not yet have official FDA-approved indications for routine clinical practice. However, it is being extensively used in approved clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

• Glioblastoma Multiforme (GBM): Used to treat aggressive brain tumors, especially in patients whose tumors have specific genetic markers.
• Chronic Lymphocytic Leukemia (CLL): Used for patients who have not responded to other targeted therapies or who have a specific genetic deletion (17p deletion).
• Small Cell Lung Cancer (SCLC): Investigated as a way to overcome resistance to standard treatments.
• Advanced Solid Tumors: Used in trials for various cancers that have spread to other parts of the body.

Non-oncological Uses:

• There are currently no non-oncological uses for CC-115 in clinical trials.

Dosage and Administration Protocols

Because CC-115 is a targeted oral therapy, it is much more convenient for patients than many injectable treatments. However, because it is potent, the dosage must be strictly managed by an oncologist.

Special Considerations

• Renal/Hepatic Insufficiency: There is currently no standard dose adjustment for mild kidney issues. However, because the drug is processed through the liver, patients with moderate to severe liver (hepatic) issues may require a lower dose or closer monitoring of liver enzymes.

Clinical Efficacy and Research Results

Recent clinical studies (between 2020 and 2025) have highlighted the promising potential of CC-115, particularly in difficult-to-treat cancers.

• Brain Tumor Breakthroughs: In trials for glioblastoma, CC-115 demonstrated the ability to cross the blood-brain barrier, which is a major hurdle for most cancer drugs. Numerical data showed that the drug reached therapeutic levels in brain tissue, leading to “Stable Disease” in a subset of patients who had failed all other treatments.
• Leukemia Response: In Phase 1 and 2 trials for Chronic Lymphocytic Leukemia (CLL), CC-115 showed a high Objective Response Rate (ORR). Specifically, patients with the high-risk “17p deletion” genetic marker saw significant reductions in lymph node size.
• Disease Progression: Studies show that by blocking both DNA-PK and mTOR, CC-115 can delay the time it takes for a tumor to start growing again (Progression-Free Survival) compared to drugs that only block one pathway.

Safety Profile and Side Effects

While CC-115 is a targeted therapy and generally better tolerated than traditional chemotherapy, it still has a distinct safety profile that doctors monitor closely.

Common Side Effects (>10%):

• Fatigue: A general sense of tiredness or lack of energy.
• Hyperglycemia: High blood sugar levels (since mTOR is involved in how the body processes sugar).
• Nausea/Diarrhea: Mild to moderate digestive upset.
• Skin Rash: Acne-like rashes or dry skin.

Serious Adverse Events:

• Pneumonitis: Inflammation of the lung tissue (rare but serious).
• Stomatitis: Painful sores or inflammation in the mouth.
• Liver Enzyme Elevation: Temporary stress on the liver.

Black Box Warning

• There is no FDA Black Box Warning for CC-115 at this time.

Management Strategies:

• Sugar Control: Patients may need to monitor their blood glucose levels and follow a low-sugar diet during treatment.
• Mouth Care: Using alcohol-free mouthwashes can help prevent stomatitis.
• Liver Monitoring: Regular blood tests are mandatory to ensure the drug is not causing hidden liver stress.

Research Areas

CC-115 is a significant focus in Immunotherapy and Regenerative Medicine research. Because DNA-PK is involved in how the body’s immune cells (like T-cells) develop, scientists are studying if CC-115 can be used to “prime” the immune system to recognize cancer more effectively.

Additionally, in regenerative medicine research, CC-115 is being used to study how healthy stem cells repair DNA compared to cancer stem cells. The goal is to find a “therapeutic window” where we can kill cancer stem cells without damaging the body’s natural regenerative stem cells in the bone marrow or gut.

Patient Management and Practical Recommendations

To ensure the best results and highest safety, patients should follow specific guidelines while taking CC-115.

Pre-treatment Tests to be Performed:

• Fasting Glucose: To check your baseline blood sugar.
• Comprehensive Metabolic Panel (CMP): To check liver and kidney health.
• Baseline Scans: MRI or CT scans to measure the size of the tumor.

Precautions During Treatment:

• Avoid certain medications: Do not take “CYP3A4 inhibitors” (like grapefruit juice or certain antibiotics) as they can make the drug levels in your blood dangerously high.
• Sun Protection: This drug can make your skin more sensitive to the sun. Wear sunscreen and protective clothing.

“Do’s and Don’ts” List:

• DO take your pill at the same time every day to keep the drug levels steady.
• DO tell your doctor immediately if you develop a new cough or shortness of breath.
• DON’T skip doses or try to “make up” a missed dose by taking two at once.
• DON’T start any new herbal supplements without asking your oncology team first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. CC-115 is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.